| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 |
| filingDate |
2003-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a63fe3b225ab392d6c4d354d16a3e466
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b34ef9016d2e71f0e92fa25c9c6abc97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a968abc3db534eaf3480dfe9ce41806 |
| publicationDate |
2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1535618-A1 |
| titleOfInvention |
Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| abstract |
A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired periodnof time longer than 21-28 days comprising a first composition containing at least one estrogennand/or at least one progestin in a predetermined amount to be administered in the first 21-28ndays and a second composition which contains at least one estrogen and/or at least onenprogestin in a predetermined amount higher than the amount of the first composition andncomprises a mono or multiphase sequence of pharmaceutical dosages. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008107373-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008104342-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011003778-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009511512-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1671626-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006066788-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008018872-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007059918-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1977752-A1 |
| priorityDate |
2003-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |